Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Files for 12M Secondary Offering

NEW YORK (GenomeWeb News) – Bruker has filed with the US Securities and Exchange Commission for a secondary offering of 12 million shares of common stock by two members of the Laukien family not involved in the firm's business.

Bruker will not receive any of the proceeds from the sale of the stock through this offering, it noted.

The two members of the Laukien family who are selling these shares are Marc Laukien and Isolde Laukien-Kleiner, neither of which are involved with the firm's business other than being shareholders. Simultaneously with the secondary offering, Bruker Chairman, President, and CEO Frank Laukien has agreed to purchase privately from Marc Laukien 100,000 shares of the firm's common stock.

The underwriters have a 30-day option to purchase up to an additional 1.8 million shares of common stock to cover over-allotments.

The offering price has not been set yet. Bruker's shares closed Thursday on the Nasdaq at $10.02.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.